NCT03652116View on ClinicalTrials.gov

Bupivacaine Verus Pethidine for Post Cesarean Section Pain Relief

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

April 21, 2017

Primary Completion Date

June 10, 2018

Study Completion Date

August 1, 2018

Conditions
Obstetric Pain
Interventions
DRUG

Wound infiltration by Bupivacaine

Subcutaneous and subrectal infiltration with 0.25 % Bupivacaine diluted in 20 ml normal saline before closure of the wound

DRUG

Wound infiltration by Pethidine

Subcutaneous and subrectal infiltration with 50 mg pethidine diluted in 20 ml normal saline before closure of the wound

Trial Locations (1)

002

Ain SHams Maternity Hospital, Cairo

All Listed Sponsors
lead

Ain Shams University

OTHER

NCT03652116 - Bupivacaine Verus Pethidine for Post Cesarean Section Pain Relief | Biotech Hunter | Biotech Hunter